Page 1

EX - 99.1 2 ptct - 20210504ex9919ca02a.htm EX - 99.1 PTC / THERAPEUTICS EXHIBIT 99.1 PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results - PTC518 demonstrated dose - dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - - Total net revenue of $ 118 million ; 73 % increase over first quarter 2020 - - DMD franchise net product revenue of $ 90 million ; 32 % increase over first quarter 2020 - - PTC has clinical trials ongoing in multiple disease areas , three of which are registration directed studies - SOUTH PLAINFIELD , N.J. , May 4 , 2021 PTC Therapeutics , Inc. ( NASDAQ : PTCT ) today announced a corporate update and financial results for the first quarter ending March 31 , 2021 . " Overall PTC has had a strong performance this quarter through all aspects of the company from discovery to commercial revenue , " said Stuart W. Peltz , Ph.D. , Chief Executive Officer , PTC Therapeutics , Inc. " I would like to highlight the continued strong growth of the DMD franchise which has had one of our largest quarterly revenues to date . The other key milestone was the positive preliminary results in our PTC518 Huntington's disease program demonstrating dose dependent lowering of the HTT mRNA . Analogous to the SMA program we are now well positioned with a clear path for success . " ● Key First Quarter and Other Corporate Updates : ● The Duchenne muscular dystrophy ( DMD ) franchise had a total net product revenue of $ 90 million for Translarna ™ ( ataluren ) and Emflaza® ( deflazacort ) in the first quarter of 2021. This represents 32 % growth over the first quarter of 2020 and one of PTC's strongest quarterly commercial revenues to date . 0 Broader uptake due to new patients in existing geographies and geographic expansion drove Translarna growth . 0 Emflaza revenue growth was primarily due to increased new prescriptions , high compliance , and fewer discontinuations . In March 2021 , the European Medicines Agency ( EMA ) approved Evrysdi ™ ( risdiplam ) in the European Union ( EU ) . The first sale of Evrysdi in this region was recorded the following day , triggering a $ 20 million milestone payment to PTC . Evrysdi is a product of a collaboration between PTC , Roche and the SMA Foundation . Preliminary results from the PTC518 Phase 1 healthy volunteer trial demonstrated dose - dependent reduction of Huntington mRNA beyond the 30-50 % target . PTC received Gallup's Don Clifton Strengths - Based Culture Award , which reflects the Company's ongoing deep commitment to its employees .